Endoscopic Papillectomy for Early Ampullary Tumors: Long-term Results of the First Large Multicenter Prospective Study
NCT ID: NCT01764503
Last Updated: 2013-03-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
93 participants
OBSERVATIONAL
2003-09-30
2009-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It has been demonstrated that ampullary adenomas have a malignant potential mimicking the "adenoma-adenocarcinoma" sequence already described in the colon. So, a complete removal is mandatory. The only exception is represented by subnormal ampulla with low grade dysplasia (LGD) adenoma discovered during screening follow-up of FAP patients. In these cases the situation can be stable during several years leading to simple, annual or biannual surveillance. Historically, the treatment was surgical, associated with a high mortality and morbidity rate for pancreaticoduodenectomy (PD) and a high recurrence rate for transduodenal resection (26 to 43%). Endoscopic papillectomy (EP) represents an alternative for patients with a benign or at least non-invasive ampullary tumor. Unlike thermal ablative methods by laser photoablation or argon plasma destruction, EP allows adequate histologic evaluation especially in case of en-bloc resection. This technique has been increasingly used in the last decade with very promising results. Nevertheless the long-term results have mainly been reported in retrospective monocentric series.
We intended to evaluate, in the first large multicenter prospective study, the long-term results of endoscopic papillectomy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predictors of Therapeutic Success and Adverse Events in Endoscopic Ampullectomy
NCT06648746
Prevalence of Small Bowel Polyps in Patients With Sporadic Duodenal Adenomas
NCT02470416
Hybrid-APC Margin Ablation to Prevent Post EMR Adenoma Recurrence
NCT04015765
French Register of Duodenal Adenomas Characterization and Evaluation of Endoscopic Mucosectomy
NCT03031704
Computer Assisted Measurement of Colorectal Polyps
NCT02970760
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Investigators were 11 experienced endoscopists (10 centers) specialized in pancreaticobiliary diseases and selected as follows: at least 4 years of endoscopic retrograde cholangiopancreatography (ERCP) practice with at least six EP in the last 3 years. The procedure was standardized: submucosal injection of saline solution was reserved to duodenal extension around the ampulla; a standard polypectomy snare was used with endocut current; resection has to be performed in one fragment, the piece-meal technique was only accepted for lesions larger than 2 cm. The size of the lesion was estimated by comparison with the opened snare. The ampullary tumor was snared at the base and constant tension was applied to the snare loop during electrocautery until the lesion was sectioned. The endoscopist had to mention if the procedure was considered complete or not. When needed, hemostasis was performed by injection of diluted adrenalin (1:10 000) and/or hemoclips. Realization of any additional procedures (stone removal, biliary or pancreatic sphincterotomy, biliary or pancreatic stent placement…) were left to the endoscopist decision and recorded. Patients were hospitalized for at least 2 days after the procedure. During the first 24 hours, fasting and proton pomp inhibitor (PPI) (+/- antibiotics) administration were recommended. Feeding was accepted on day 2 in the absence of complications and final discharge at day 3. Complications occurring after discharge were recorded when reported by other health care provider or by the patient at the subsequent FU session. We documented the complications and graded their severity according to the Consensus Criteria. Treatment of the complications was recorded. Finally, the length of hospital stay and the morbidity rate were calculated.
Size, number of fragments, and final staging were stated. In case of duodenal submucosal invasion a complementary surgery was discussed. In case of absence of tumor on the resected specimen, an experienced pathologist (JYS) performed a second reading of initial biopsies.
A first endoscopic control was performed after 4 to 8 weeks with retrieval of the eventual stents and systematic biopsies. In case of evident persistence of tumoral tissue a complementary resection was done, if possible, with a new endoscopic control 4 weeks later. Follow-up (F-U) was performed at 6, 12, 18, 24 and 36 months, including clinical examination, duodenoscopy with biopsies and EUS +/- ERCP. Therapeutic success was concluded in case of: 1) R0 resection = absence of invasion of duodenal submucosa on the resected specimen and complete excision of the lesion (no residual tumoral tissue at the first endoscopic control with biopsies, or at the second control in case of iterative resection) 2) no recurrence during long-term F-U. Therapeutic failure was defined as: - early failure in case of duodenal submucosal invasion on the resected specimen and/or positive biopsies without possibility of complementary resection at first control (or second control in case of iterative resection); - late failure in case of positive biopsies (persistence or recurrence) during the FU.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Two other criteria were needed in asymptomatic patients with LGD :
* an ampullary size \> 1 cm at endoscopy in case of Familial Adenomatous Polyposis (FAP) ;
* two series of positive biopsies in case of sporadic tumors
* uT1N0 lesion at EUS (tumor without invasion of the muscularis propria (MP) of the duodenum and no suspicious lymph nodes)
* without intraductal growth (pancreatic and/or common bile duct)
Exclusion Criteria
* metastatic disease at CT-scan;
* advanced tumor at duodenoscopy (ulceration or induration involving the duodenal roof of the papilla);
* advanced tumor (uT2 = invasion of the MP without invasion of the pancreas ; uT3 = invasion of pancreas and/or N+ suspicious lymph nodes) and/or intraductal invasion at EUS
* absence of adenoma on the resected specimen.
* adenoma not confirmed
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Société Française d'Endoscopie Digestive
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gincul Rodica
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rodica Gincul, MD
Role: PRINCIPAL_INVESTIGATOR
Société Française d'Endoscopie Digestive
Bertrand Napoleon, MD
Role: STUDY_CHAIR
Société Française d'Endoscopie Digestive
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Société Française d'Endoscopie Digrestive
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Napoleon B, Gincul R, Ponchon T, Berthiller J, Escourrou J, Canard JM, Boyer J, Barthet M, Ponsot P, Laugier R, Helbert T, Coumaros D, Scoazec JY, Mion F, Saurin JC; Societe Francaise d'Endoscopie Digestive (SFED, French Society of Digestive Endoscopy). Endoscopic papillectomy for early ampullary tumors: long-term results from a large multicenter prospective study. Endoscopy. 2014 Feb;46(2):127-34. doi: 10.1055/s-0034-1364875. Epub 2014 Jan 29.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
24
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.